In the past week, BCLI stock has gone up by 0.83%, with a monthly decline of -50.21% and a quarterly plunge of -78.86%. The volatility ratio for the week is 11.99%, and the volatility levels for the last 30 days are 13.90% for Brainstorm Cell Therapeutics, Inc The simple moving average for the past 20 days is -27.57% for BCLI’s stock, with a -77.39% simple moving average for the past 200 days.
Is It Worth Investing in Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) Right Now?
The 36-month beta value for BCLI is also noteworthy at 0.30. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BCLI is 4.55M, and at present, short sellers hold a 2.41% of that float. The average trading volume of BCLI on November 18, 2024 was 67.52K shares.
BCLI) stock’s latest price update
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) has experienced a rise in its stock price by 7.08 compared to its previous closing price of 1.13. However, the company has seen a gain of 0.83% in its stock price over the last five trading days. prnewswire.com reported 2024-11-14 that Conference call planned for later in Q4 2024 to provide updates on NurOwn® program NEW YORK, Nov. 14, 2024 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update. “BrainStorm’s primary focus continues to be preparing for the upcoming Phase 3b registration trial of NurOwn in ALS,” said Chaim Lebovits, President and CEO of Brainstorm.
Analysts’ Opinion of BCLI
Many brokerage firms have already submitted their reports for BCLI stocks, with Maxim Group repeating the rating for BCLI by listing it as a “Buy.” The predicted price for BCLI in the upcoming period, according to Maxim Group is $12 based on the research report published on February 04, 2021 of the previous year 2021.
Maxim Group gave a rating of “Buy” to BCLI, setting the target price at $6 in the report published on December 19th of the previous year.
BCLI Trading at -52.23% from the 50-Day Moving Average
After a stumble in the market that brought BCLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.82% of loss for the given period.
Volatility was left at 13.90%, however, over the last 30 days, the volatility rate increased by 11.99%, as shares sank -46.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -68.67% lower at present.
During the last 5 trading sessions, BCLI rose by +0.83%, which changed the moving average for the period of 200-days by -79.05% in comparison to the 20-day moving average, which settled at $1.6705. In addition, Brainstorm Cell Therapeutics, Inc saw -70.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCLI starting from Lebovits Chaim, who purchase 1,836 shares at the price of $3.43 back on Oct 01 ’24. After this action, Lebovits Chaim now owns 80,960 shares of Brainstorm Cell Therapeutics, Inc, valued at $6,292 using the latest closing price.
Lebovits Chaim, the President & CEO of Brainstorm Cell Therapeutics, Inc, purchase 22,000 shares at $0.23 during a trade that took place back on Sep 30 ’24, which means that Lebovits Chaim is holding 1,186,865 shares at $5,016 based on the most recent closing price.
Stock Fundamentals for BCLI
Current profitability levels for the company are sitting at:
- -117.23 for the present operating margin
- -0.86 for the gross margin
The net margin for Brainstorm Cell Therapeutics, Inc stands at -91.7. The total capital return value is set at 3.01.
Based on Brainstorm Cell Therapeutics, Inc (BCLI), the company’s capital structure generated -0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -13.47. The debt to equity ratio resting at -0.13. The interest coverage ratio of the stock is -177.12.
Currently, EBITDA for the company is -16.93 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 51.11. The receivables turnover for the company is 3.48for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.05.
Conclusion
In summary, Brainstorm Cell Therapeutics, Inc (BCLI) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
